SOPHiA GENETICS (NASDAQ:SOPH) CTO Sells 5,000 Shares of Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) CTO Abhimanyu Verma sold 5,000 shares of the firm’s stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $7.60, for a total transaction of $38,000.00. Following the completion of the sale, the chief technology officer owned 182,171 shares in the company, valued at $1,384,499.60. This represents a 2.67% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Abhimanyu Verma also recently made the following trade(s):

• On Tuesday, August 4th, Abhimanyu Verma sold 5,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $6.95, for a total value of $34,750.00.
• On Monday, July 6th, Abhimanyu Verma sold 5,285 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.10, for a total value of $26,953.50.
• On Thursday, June 25th, Abhimanyu Verma sold 6,944 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.51, for a total transaction of $38,261.44.

SOPHiA GENETICS Trading Down 0.5%

NASDAQ SOPH traded down $0.04 on Monday, reaching $7.67. The company had a trading volume of 408,022 shares, compared to its average volume of 221,806. The business has a 50 day moving average of $5.63 and a two-hundred day moving average of $5.15. SOPHiA GENETICS SA has a fifty-two week low of $2.96 and a fifty-two week high of $7.88. The firm has a market cap of $643.44 million, a price-to-earnings ratio of -6.67 and a beta of 0.96. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.69 and a quick ratio of 2.55.

SOPHiA GENETICS (NASDAQ:SOPH) last issued its quarterly earnings data on Tuesday, August 4th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.05). SOPHiA GENETICS had a negative return on equity of 132.47% and a negative net margin of 93.86%.The company had revenue of $23.31 million for the quarter, compared to the consensus estimate of $21.72 million. Analysts forecast that SOPHiA GENETICS SA will post -0.77 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of SOPH. Sei Investments Co. bought a new position in SOPHiA GENETICS during the first quarter valued at about $1,772,000. 1492 Capital Management LLC purchased a new position in SOPHiA GENETICS in the fourth quarter valued at about $973,000. Royce & Associates LP bought a new position in shares of SOPHiA GENETICS during the 4th quarter valued at approximately $2,009,000. Hodges Capital Management Inc. bought a new position in shares of SOPHiA GENETICS during the 1st quarter valued at approximately $2,157,000. Finally, Royal Bank of Canada increased its stake in shares of SOPHiA GENETICS by 3,130.2% during the 1st quarter. Royal Bank of Canada now owns 19,381 shares of the company’s stock worth $96,000 after purchasing an additional 18,781 shares during the last quarter. Hedge funds and other institutional investors own 31.59% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on SOPH shares. BTIG Research boosted their target price on shares of SOPHiA GENETICS from $8.00 to $9.00 and gave the company a “buy” rating in a report on Wednesday, August 5th. HC Wainwright boosted their price objective on SOPHiA GENETICS from $12.00 to $14.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. Zacks Research upgraded SOPHiA GENETICS to a “hold” rating in a research report on Tuesday, July 21st. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of SOPHiA GENETICS in a report on Friday, July 17th. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, SOPHiA GENETICS currently has an average rating of “Hold” and a consensus price target of $10.00.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.